Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 4;22(1):853.
doi: 10.1186/s12885-022-09939-w.

Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study

Mengmeng Song #  1   2   3 , Tong Liu #  1   2   3 , Hai Liu #  4 , Qi Zhang  1   2   3 , Qingsong Zhang  5 , Yiming Wang  6 , Xiangming Ma  6 , Liying Cao  7 , Hanping Shi  8   9   10
Affiliations

Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study

Mengmeng Song et al. BMC Cancer. .

Abstract

Background and aims: High-sensitivity C-reactive protein (hs-CRP) levels and metabolic syndrome (MetS) are known to be associated with an increased incidence of different cancers. We aimed to evaluate the effect of MetS combined with high hs-CRP levels on the risk of primary liver cancer (PLC).

Methods: Participants were recruited from the Kailuan cohort study and were classified into four groups according to the presence or absence of MetS and inflammation (hs-CRP ≥ 3 or < 3 mg/L). The associations of MetS and inflammation with the risk of PLC were assessed using Cox proportional hazards models.

Results: This study included 92,770 participants. The mean age was 51.4 years old. Over a median follow-up of 13.02 years, 395 participants were diagnosed as PLC. Compared to the control participants without inflammation (hs-CRP < 3 mg/L) and MetS (n = 69,413), participants with high hs-CRP levels combined with MetS (n = 2,269) had a higher risk of PLC [hazard ratios (HR) 2.91; 95% confidence interval (CI), 1.77-4.81], and participants with high hs-CRP levels and without MetS (n = 14,576) had the same trend (HR, 1.36; 95%CI, 1.05-1.75). However, participants with low hs-CRP levels and MetS (n = 6,512) had no significant association with an elevated risk of PLC (HR, 1.18; 95%CI, 0.76-1.82). After excluding participants who had cancer during the first year of follow-up, sensitivity analysis showed the same trend. In addition, co-occurrence of MetS and high hs-CRP levels had significant interactive effects on the risk of PLC between the sexes (P < 0.001) and the patients with HBV infection (P = 0.012).

Conclusions: Participants with co-occurrence of MetS and high hs-CRP levels have an elevated risk of PLC.

Trial registration: Kailuan study, ChiCTR-TNRC-11001489. Registered 24 August, 2011-Retrospectively registered, http://www.chictr.org.cn/showprojen.aspx?proj=8050.

Keywords: Hs-CRP; Incidence; Metabolic syndrome; Primary liver cancer.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to declare.

Figures

Fig. 1
Fig. 1
Flow chart of study participants. Hs-CRP, high sensitivity C-reactive protein; MetS, metabolic syndrome
Fig. 2
Fig. 2
Subgroup analysis of the association between concurrence of MetS and high hs-CRP levels and PLC risk. Note: Adjusted models were adjusted for age (every 10 years), sex, family income, educational background, marital status, HBV infection, cirrhosis, fatty liver, BMI, TC, ALT, SUA, smoking status, drinking status, physical activity, sedentary lifestyle, tea consumption, salt intake, high-fat diet, family history of cancer
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49. - PubMed
    1. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103–117. doi: 10.1146/annurev-med-090514-013832. - DOI - PubMed
    1. Sohn W, Lee HW, Lee S, Lim JH, Lee MW, Park CH, Yoon SK. Obesity and the risk of primary liver cancer: a systematic review and meta-analysis. Clin Mol Hepatol. 2021;27(1):157–174. doi: 10.3350/cmh.2020.0176. - DOI - PMC - PubMed
    1. Ohkuma T, Peters SAE, Woodward M. Sex differences in the association between diabetes and cancer: a systematic review and meta-analysis of 121 cohorts including 20 million individuals and one million events. Diabetologia. 2018;61(10):2140–2154. doi: 10.1007/s00125-018-4664-5. - DOI - PMC - PubMed
    1. He YN, Zhao WH, Zhao LY, Yu DM, Zhang J, Yang XG, Ding GG. [Prevalence of metabolic syndrome in Chinese adults in 2010–2012] Zhonghua Liu Xing Bing Xue Za Zhi. 2017;38(2):212–215. - PubMed

Substances